Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley.

Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR ...

Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s ...

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

Biotechunternehmen Halozyme Therapeutics hat Interesse an der Hamburger Evotec. Die Kalifornier teilten am Donnerstagabend ...

德国汉堡 - 专注于药物发现和开发的制药公司Evotec SE今天向美国证券交易委员会提交了一份临时公告，回应了最近的媒体猜测。这家在法兰克福证券交易所以EVO为股票代码上市的公司，对有关其业务运营的报道作出了澄清。 在公告中，Evotec的首席执行官Christian Wojczewski表示："我们经常评估潜在的战略机会以提升股东价值，并将继续这样做。"Wojczewski强调，虽然公司愿意探 ...

(Bloomberg) -- Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German drug developer at €2 billion ($2.1 ...

Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...